| Citation: |
Birnbaum, H., Shi, L., Pike, C., Kaufman, R., Sun, P., & Cifaldi, M. (2009). Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.
Expert Opinion on Pharmacotherapy, 10
(2),
255-269.
|
| Title: |
Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature |
| Authors: |
Birnbaum, H., Shi, L., Pike, C., Kaufman, R., Sun, P., & Cifaldi, M. |
| Year: |
2009 |
|
Journal/Publication:
|
Expert Opinion on Pharmacotherapy |
| Publisher: |
Informa Healthcare |
| DOI: |
https://doi.org/10.1517/14656560802682163
|
| Full text: |
http://www.tandfonline.com/doi/abs/10.1517/14656560802682163
|
| Peer-reviewed? |
Yes
|
| NIDILRR-funded? |
No
|
|
Research design:
|
Systematic review / meta-analysis
|
| Background: |
Rheumatoid arthritis causes pain and serious functional impacts and substantially affects patients' daily lives, including their ability to work. |
|
Purpose:
|
The purpose of the paper is to examine recent studies of patients with Rheumatoid Arthritis treated with TNF antagonists and the impacts these therapies have on the workplace. |
|
Setting:
|
This study is a systematic review. The included studies were undertaken in various locations and settings. |
|
Study sample: |
The sample included 133 articles and 14 poster abstracts that studied the impact of Rheumatoid Arthritis. |
|
Intervention:
|
The intervention was medical treatment of Rheumatoid Arthritis including TNF antagonists and DMARDs. |
|
Control or comparison condition:
|
There were no comparison or control conditions. |
|
Data collection and analysis:
|
The studies were categorized into three distinct groups: general RA, DMARD, and TNF-antagonist literature. The general RA literature was used as a backdrop when examining literature regarding the impacts of DMARDs and the emergence of anti-TNF therapies on the workplace. |
|
Findings:
|
The results of early studies of the TNF antagonists varied regrading their effects on patients with RA in the workplace. Recent studies of adalimuamab showed positive impacts across a range of workplace burdens. |
|
Conclusions:
|
Treatments such as adalimuamab may help employees with RA to remain in the workforce and lead to reduced workplace costs to the employers and employees. |